WISARD (NEAT33) - Switch Study Mutation Ripivirine Dolutegravir

​

An open-label, multicentre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG/RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N

 

 

Sponsor number: SSCR105/NEAT33 

EudraCT: 2017-004040-38 

Sponsor: NEAT ID 

 

Phase: IIIb

 

Indication:  HIV-1 infected patients with a history of virological failure to NNRTIs and having the K103N mutation

 

Countries: UK, France, Germany, Belgium, Spain, Italy, Ireland

​

Sites: 36

​

Status: Recruitment Closed

​

Posters: E-poster at IAS 2021

E-poster at AIDS 2022